Accessibility Menu
Invivyd logo

Invivyd

(NASDAQ) IVVD

Current Price$0.74
Market Cap$218.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-96%
5 YearN/A
1 Year+3%
1 Month-20%
Invivyd last closing stock price
MetricPriceDate
Last closeUSD 0.742026-07-17
Invivyd stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.22%USD 0.782026-07-10
1 month-20.26%USD 0.932026-06-17
3 month-57.33%USD 1.742026-04-17
Year to date-69.94%USD 2.472025-12-31
1 year+2.88%USD 0.722025-07-17
3 year-45.8%USD 1.372023-07-18
Since inception-96.44%USD 20.882021-08-06

Invivyd Financials at a Glance

Market Cap

$218.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$55.87M

Net Income (TTM)

-$77.60M

EPS (TTM)

-$0.36

P/E Ratio

-2.08

Dividend

$0.00

Beta (Volatility)

1.61 (High)

Price

$0.74

Volume

92,331

Open

$0.78

Previous Close

$0.74

Daily Range

$0.74 - $0.79

52-Week Range

$0.48 - $3.07

Estimated Earnings Date

Aug 13, 2026

IVVD: Motley Fool Moneyball Superscore

59

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Invivyd

Invivyd, Inc. is a biopharmaceutical company focused on developing antibody-based solutions to address serious viral infectious diseases, initially concentrating on SARS-CoV-2. The company distinguishes itself through its rapid response capabilities and innovative approach to antibody discovery and development. By leveraging cutting-edge research and strategic partnerships, Invivyd aims to deliver next-generation therapeutics that meet significant unmet medical needs.

Products and Services

PEMGARDA: An investigational monoclonal antibody authorized for emergency use in COVID-19 pre-exposure prophylaxis for certain immunocompromised patients.

VYD2311: A next-generation monoclonal antibody candidate in Phase 1 trials, targeting prominent SARS-CoV-2 variants.

Antibody discovery and development: Utilizing advanced technology for creating robust therapeutic candidates.

What Makes Invivyd, Inc. Special

Invivyd's unique approach lies in its dynamic and rapid response capabilities in tackling emerging infectious threats. By focusing on antibody discovery using cutting-edge technology, the company is positioned to address significant unmet needs in the biopharmaceutical sector.

Five Things You Need to Know

PEMGARDA has received emergency use authorization for COVID-19 prophylaxis in immunocompromised individuals.

VYD2311 is undergoing Phase 1 clinical trials for COVID-19, with positive data on safety and pharmacokinetics.

Invivyd relies on partnerships for commercial manufacturing, including with WuXi Biologics.

The company's strategy includes expanding its antibody pipeline to address various viral diseases.

Invivyd actively monitors SARS-CoV-2 variants to stay ahead of viral evolution.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Employees

122

CEO

William E. Duke, Jr., MBA

Headquarters

New Haven, CT 02451, US

IVVD Financials

Key Financial Metrics (TTM)

Gross Margin

92.02%

Operating Margin

-146.38%

Net Income Margin

-138.90%

Return on Equity

-53.48%

Return on Capital

-22.77%

Return on Assets

-32.10%

Earnings Yield

-48.08%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$218.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

294.61M

Volume

92.33K

Avg. Volume

4.14M

Financials (TTM)

Gross Profit

$51.41M

Operating Income

-$81.77M

EBITDA

-$75.72M

Operating Cash Flow

-$78.72M

Capital Expenditure

-$737.00K

Free Cash Flow

-$79.46M

Cash & ST Invst.

$184.15M

Total Debt

$8.63M

Invivyd Performance Analysis

Invivyd annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 25,384,000N/A
20252025-12-31USD 53,426,000110.5%
Invivyd sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-304.3%
Q32025-09-3011.4%
Q42025-12-3131.1%
Q12026-03-31-20.1%
Invivyd annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.238.9%
20232023-12-31USD -1.81-18.6%
20242024-12-31USD -1.43-21.0%
20252025-12-31USD -0.30-78.7%
Invivyd sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3014.3%
Q32025-09-3050.0%
Q42025-12-31-7.2%
Q12026-03-31-102.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$13.74M

+21.6%

Gross Profit

$12.20M

+16.5%

Gross Margin

88.76%

N/A

Market Cap

$218.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.79M

N/A

Employees

122

N/A

Net Income

-$41.40M

-154.2%

EBITDA

-$40.89M

-162.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$184.15M

+283.0%

Total Debt

$8.63M

+864.9%

Accounts Receivable

$12.21M

+39.5%

Inventory

$25.45M

+5658.4%

Long Term Debt

$7.03M

N/A

Short Term Debt

$1.59M

+78.1%

Return on Assets

-32.10%

N/A

Return on Invested Capital

-38.92%

N/A

Free Cash Flow

-$42.44M

-99.5%

Operating Cash Flow

-$41.71M

-97.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OBIOOrchestra BioMed Holdings, Inc.
$3.68-1.08%
CDXSCodexis, Inc.
$2.24+3.70%
OABIOmniAb, Inc.
$2.12+3.92%
TARAProtara Therapeutics, Inc.
$4.10+0.49%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$95.04-0.02%
PATHUiPath
$12.15+0.01%
JOBYJoby Aviation
$7.23-0.01%
TAT&T
$21.81-0.01%

Questions About IVVD

What is the current price of Invivyd?

Invivyd is trading at $0.74 per share.

What is the 52-week range for Invivyd?

Over the past 52 weeks, Invivyd has traded between $0.48 and $3.07.

How much debt does Invivyd have?

As of the most recent reporting period, Invivyd reported total debt of $8.63M.

How much cash does Invivyd have on hand?

Invivyd reported $184.15M in cash and cash equivalents in its most recent financial results.

What is Invivyd’s dividend yield?

Invivyd does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.